Fig. 7

a High-fat diet (HFD)-Obese, HFD-Lean, and low-fat diet (LFD) TAN mice (n = 5/arm) were killed following primary tumor regression to assess residual disease. HFD-Obese mice weighed significantly more than HFD-Lean and LFD mice (37.9 ± 5.3 g vs. 29.8 ± 1.6 g vs. 28.4 ± 4.9 g, respectively; p = 0.004). b HFD-Obese TAN mice had elevated body fat percentage relative to HFD-Lean and LFD mice (37.9 ± 4.5% vs. 30.1 ± 2.0% vs. 23.7 ± 11.5%, respectively; p = 0.004). c HFD-Obese TAN mice had elevated fasting serum glucose levels relative to HFD-Lean and LFD mice (99.6 ± 15.3 mg/dl vs. 70.3 ± 10.0 mg/dl vs. 76.2 ± 6.8 mg/dl, respectively; p = 0.009). d Representative bright-field and fluorescence imaging of residual disease within the mammary glands of mice following tumor regression. e Representative residual lesion quantification of rtTA-positive droplets by droplet digital PCR (ddPCR). f Representative control mammary tissue quantification of rtTA-positive droplets by ddPCR. g HFD-Obese mice harbored a significantly greater number of rtTA-positive tumor cells in residual lesions relative to HFD-Lean and LFD mice (12,550 ± 991 vs. 7339 ± 2182 vs. 4793 ± 1618 cells, respectively; p < 0.001). h Recurrence-free survival of TAN mice (n = 15/arm) following primary tumor induction by orthotopic injection of MTB/TAN tumor cells and subsequent doxycycline withdrawal. Recurrence-free survival was significantly poorer for HFD-Obese mice than for HFD-Lean and LFD mice (log-rank p = 0.009, HR 5.81, 95% CI 1.28–26.36). Dot plots show mean data. Error bars represent the SEM. *p < 0.05, **p < 0.01